Abstract
Interstitial lung disease (ILD) is one of the most frequent and severe visceral complications of connective tissue diseases (CTDs).1 Despite the recent approval of nintedanib for the treatment of fibrosing progressive ILDs other than idiopathic pulmonary fibrosis,2 management of CTD-ILDs remains challenging. While fibrosing ILD represents at least 50% of ILD cases in patients with rheumatoid arthritis, the frequency of fibrosing subsets in CTDs is significantly lower.1,3 Therefore, immunosuppressants continue to be the most commonly adopted therapy for CTD-ILDs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
